Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

This study is ongoing, but not recruiting participants.

Study NCT00324870 Information provided by Johns Hopkins University

First Received: May 10, 2006 Last Updated: December 3, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Publications:

Pili R, Wilky B, Salumbides B, et al.: Phase I/II trial of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with renal cell carcinoma: phase I safety and pharmacokinetic/pharmacodynamic results. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-371, 2008.